Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature Reviews Rheumatology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrrheum.2011.62PMID 21637317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma.

  2011cited by this paper
• Non‐Hodgkin lymphoma and autoimmunity: Does gender matter?

  2011cited by this paper
• Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

  2011cited by this paper
• Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.

  2010cited by this paper
• Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.

  2010cited by this paper
• Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.

  2010cited by this paper
• Secondary tumours in Sjögren's syndrome.

  2010cited by this paper
• Antiphospholipid antibodies and malignancies.

  2010cited by this paper
• Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation

  2010cited by this paper
• Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.

  2010cited by this paper
• Malignancies in systemic lupus erythematosus.

  2010cited by this paper
• Malignancy in systemic lupus erythematosus: what have we learned?

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Population‐based study of autoimmune conditions and the risk of specific lymphoid malignancies

  2009cited by this paper
• The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research

  2009cited by this paper
• Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.

  2009cited by this paper
• Autoimmunity and lymphomagenesis

  2009cited by this paper
• Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

  2009cited by this paper
• B-cell-depletion therapy in SLE—what are the current prospects for its acceptance?

  2009cited by this paper
• Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.

  2009cited by this paper
• Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

  2009cited by this paper
• Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas

  2009cited by this paper
• Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

  2009cited by this paper
• Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.

  2008cited by this paper
• Editorial: Is BAFF the murderer in lupus?

  2008cited by this paper
• Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.

  2008cited by this paper
• Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma.

  2008cited by this paper
• Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors.

  2007cited by this paper
• The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.

  2007cited by this paper
• Multistep pathogenesis of autoimmune disease.

  2007cited by this paper
• B-cell targeting: a novel approach to immune intervention today and tomorrow

  2007cited by this paper
• B-cell lymphoproliferation in chronic inflammatory rheumatic diseases

  2007cited by this paper
• Epstein–Barr virus and Burkitt lymphoma

  2007cited by this paper
• Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection.

  2007cited by this paper
• The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study

  2007cited by this paper
• The non‐Hodgkin lymphomas: A review of the epidemiologic literature

  2007cited by this paper
• Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

  2006cited by this paper
• Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation.

  2006cited by this paper
• Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.

  2006cited by this paper
• Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.

  2006cited by this paper
• Treatment of rheumatoid arthritis with rituximab: an update and possible indications.

  2006cited by this paper
• Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

  2006cited by this paper
• Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma.

  2006cited by this paper
• [BAFF: A regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer].

  2006cited by this paper
• Incidence of cancer in a cohort of patients with primary Sjogren's syndrome.

  2006cited by this paper
• BAFF, APRIL and human B cell disorders.

  2006cited by this paper
• [BAFF: A regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer].

  2006cited by this paper
• Risk of lymphoma in patients with RA treated with anti-TNFα agents

  2005cited by this paper
• Long term remission of Sjögren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)

  2005cited by this paper
• An international cohort study of cancer in systemic lupus erythematosus.

  2005cited by this paper
• Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

  2005cited by this paper
• Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

  2005cited by this paper
• Repeated B lymphocyte depletion therapy in rheumatoid arthritis: 5 year follow-up.

  2005cited by this paper
• The epidemiology of non‐Hodgkin lymphoma

  2005cited by this paper
• The risk of lymphoma development in autoimmune diseases: a meta-analysis.

  2005cited by this paper
• Is there a future for TNF promoter polymorphisms?

  2004cited by this paper
• Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.

  2004cited by this paper
• The use of TNF-α blocking agents in rheumatoid arthritis: an overview

  2004cited by this paper
• Cancer: An inflammatory link

  2004cited by this paper
• Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy

  2003cited by this paper
• Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus1

  2001cited by this paper
• Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group.

  2000cited by this paper

• Autoimmune disease-associated lymphomas: research progress and review

  2026cites this paper
• Disentangling the Complex Relationships Between Autoimmune Diseases and Cancer Through Polygenic Risk Scores: Evidence from a Large Prospective Study

  2025cites this paper
• Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment

  2025cites this paper
• Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases

  2025cites this paper
• Concomitant manifestations of systemic lupus erythematosus flare‐up and nodal marginal zone B‐cell lymphoma in a 41‐year‐old male patient: A challenging case report

  2024cites this paper
• Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma

  2024cites this paper
• PRIMARY SJÖGREN'S SYNDROME AND THE RISK FOR DEVELOPING LYMPHOMAS

  2024cites this paper
• The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren’s syndrome, cancers, and cancer metabolism

  2023cites this paper
• Primary colonic MALT lymphoma associated with Crohn's disease: Case report and review of the literature

  2023cites this paper
• The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study

  2023cites this paper
• Association Between Systemic Lupus Erythematosus and Cancer Morbidity and Mortality: Findings From Cohort Studies

  2022cites this paper
• Case Report: Rapid Progression of Cognitive Dysfunction as an Initial Feature of Systemic Lupus Erythematosus With Leukoencephalopathy: A Case Report and Literature Review

  2022cites this paper
• Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity

  2022cites this paper
• The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large‐scale cohort study in China

  2022cites this paper
• Arthritis and B-cell lymphoma: is the most obvious diagnosis the right one?

  2022cites this paper
• Association between systemic lupus erythematosus and cancer: findings from cohort studies and Mendelian randomization analysis

  2021cites this paper
• The Cancer Risk Profile of Systemic Lupus Erythematosus Patients

  2021cites this paper
• Lymphomagenesis predictors and related pathogenesis

  2021cites this paper
• Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis.

  2021cites this paper
• Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options

  2021cites this paper
• A case report and review of the literature

  2020influential citation
• Primary central nervous system lymphoma in a patient treated with mycophenolate mofetil for lupus nephritis

  2020cites this paper
• Diffuse large B cell lymphoma in a preceding IgG4-related disease with kidney restricted lambda light chain expression: case report and literature review

  2020cites this paper
• Birth Order, Sibship Size, Childhood Environment and Immune-Related Disorders, and Risk of Lymphoma in Lymphoid Cancer Families

  2020cites this paper
• Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival

  2019cites this paper
• Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies

  2019cites this paper
• IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development

  2019cites this paper
• 18 Lymphoproliferative Disorders in Patients with Systemic Lupus Erythematosus

  2018cites this paper
• Phenotyping Sjögren's syndrome: towards a personalised management of the disease.

  2018cites this paper
• Chapter 123 – Musculoskeletal Syndromes in Malignancy

  2017cites this paper
• Associations of Autoimmunity, Immunodeficiency, Lymphomagenesis, and Gut Microbiota in Mice with Knockins for a Pathogenic Autoantibody.

  2017cites this paper
• MiR‐30a increases MDSC differentiation and immunosuppressive function by targeting SOCS3 in mice with B‐cell lymphoma

  2017cites this paper
• The evolving concept of SLE comorbidities

  2017influential citation
• Long-term follow-up in primary Sjögren’s syndrome reveals differences in clinical presentation between female and male patients

  2017cites this paper
• The P2X7 receptor–NLRP3 inflammasome complex predicts the development of non‐Hodgkin's lymphoma in Sjogren's syndrome: a prospective, observational, single‐centre study

  2017cites this paper
• MOLECULAR AND CLINICAL SEXUAL DIMORPHISM IN SYSTEMIC AUTOIMMUNITY

  2017cites this paper
• Reduced DICER1 Expression Bestows Rheumatoid Arthritis Synoviocytes Proinflammatory Properties and Resistance to Apoptotic Stimuli

  2016cites this paper
• Acceleration of tumor growth due to dysfunction in M1 macrophages and enhanced angiogenesis in an animal model of autoimmune disease

  2016cites this paper
• Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

  2016cites this paper
• The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity

  2016cites this paper
• Hashimoto's thyroiditis or/and thyroid cancer in patients with diffuse large B-cell lymphoma

  2016cites this paper
• Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis

  2015cites this paper
• Interleukin (IL)‐22 receptor 1 is over‐expressed in primary Sjogren's syndrome and Sjögren‐associated non‐Hodgkin lymphomas and is regulated by IL‐18

  2015cites this paper
• A study of inflammatory cytokine gene polymorphisms in B-cell diseases

  2015cites this paper
• A genome-wide association study of marginal zone lymphoma shows association to the HLA region

  2015cites this paper
• A curious case of facial swelling in the night-time

  2015cites this paper
• A Case of Orbital MALT Lymphoma in a Patient with Rheumatoid Arthritis

  2015cites this paper
• Interstitial Lung Disease in Connective Tissue Diseases Other Than Systemic Sclerosis

  2015cites this paper
• Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B‐cell lymphoma patients with and without rheumatic disease

  2015cites this paper
• Lupus Eritematoso Sistémico - Terapias atuais e Novas abordagens

  2015cites this paper
• Diffuse Large B Cell Lymphoma of the Foot in a Patient with Rheumatoid Arthritis

  2015cites this paper
• ELEVATA PREVALENZA DI LINFOMI INDOLENTI B CELLULARI NON FOLLICOLARI (INFBCL ) IN PAZIENTI AFFETTI DA CARENZA ACQUISITA DI INIBITORE DELLA C1 - ESTERASI.

  2015cites this paper
• Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: a single-center experience and review of the literature.

  2014cites this paper
• A Neurologist's Guide to Safe Use of Immunomodulatory Therapies

  2014cites this paper
• Targeting Bruton's tyrosine kinase in B cell malignancies

  2014cites this paper
• Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?

  2014cites this paper
• Silicone Breast Implants as Predisposing Factor for Non-Hodgkin’s Lymphoma: An Additional Facet of Auto-Inflammatory Syndrome Induced by Adjuvant

  2014cites this paper
• Is rheumatoid arthritis a B-cell haematological disease with a predilection for the joints? Following the B cell thread to its logical conclusion.

  2014influential citation
• Early events in Sjögren's Syndrome pathogenesis: the importance of innate immunity in disease initiation.

  2014cites this paper
• Role of IL-22 pathway in primary Sjogren’s Syndrome

  2014cites this paper
• Malignancies in systemic lupus erythematosus

  2013cites this paper
• Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis

  2013cites this paper
• Challenges and approaches for the development of safer immunomodulatory biologics

  2013cites this paper
• An unusual case of glomerulonephritis in a patient with non-Hodgkin Mucosal Associated Lymphoid Tissue (MALT) B-cell lymphoma

  2013cites this paper
• Cancer complicating systemic lupus erythematosus – a dichotomy emerging from a nested case-control study

  2013cites this paper
• Cancer risk in systemic lupus: an updated international multi-centre cohort study.

  2013cites this paper
• Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship.

  2013cites this paper
• Clinical aspects of autoimmune rheumatic diseases.

  2013cites this paper
• Lymphocyte transformation and autoimmune disorders.

  2013cites this paper
• Lifestyle factors, autoimmune disease and family history in prognosis of non‐hodgkin lymphoma overall and subtypes

  2013cites this paper
• Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports

  2013cites this paper
• RO52/ TRIM21 IN B CELL PATHOLOGY

  2013cites this paper
• Staging and prognosis

  2013cites this paper
• 122 – Musculoskeletal Syndromes in Malignancy

  2013cites this paper
• Epidemiologic overview of malignant lymphoma

  2012cites this paper
• Lymphoproliferative Disorders in Patients with Systemic Lupus Erythematosus

  2012cites this paper
• B-cell lymphomagenesis in autoimmune diseases: the missing links.

  2012cites this paper
• Preferentially immunoglobulin (IgG) subclasses production in primary Sjögren’s syndrome patients

  2012cites this paper
• Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome

  2012cites this paper
• A B cell explanation for autoimmune disease: the forbidden clone returns

  2012cites this paper
• B-Cell Tolerance Defects in the B6.Aec1/2 Mouse Model of Sjögren’s Syndrome

  2012cites this paper
• Genetics of Primary Intraocular Tumors

  2012cites this paper
• Non-Hodgkin’s Lymphoma of the synovium discovered in total knee arthroplasty: a case report

  2012cites this paper
• Pathogenesis of Non-Hodgkin Lymphoma Derived from Inflammatory, Autoimmune or Immunologic Disorders

  2012cites this paper
• The NFκB pathway: a therapeutic target in glioblastoma

  2011cites this paper